中東およびアフリカのがんサポートケア製品市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2021 –2028 |
 市場規模（基準年） |
USD 378.32 Million |
 Market Size (Forecast Year) |
USD 475.40 Million |
 CAGR |
% |
| 主要市場プレーヤー |
中東およびアフリカのがん治療薬市場、薬剤タイプ別（顆粒球コロニー刺激因子（GCSFS）、エリスロポエチン刺激剤（ESA）、オピオイド鎮痛剤、モノクローナル抗体、非ステロイド性抗炎症薬（NSAID）、ビスフォスフォネート、制吐剤、抗ヒスタミン剤など）、タイプ別（ブランドおよびジェネリック）、がんタイプ別（肺がん、乳がん、前立腺がん、肝臓がん、膀胱がん、白血病、黒色腫、卵巣がん、その他のがん）、エンドユーザー別（病院、診療所、病院および学術機関など）、流通チャネル別（病院薬局、小売薬局、調剤薬局）、国別（サウジアラビア、南アフリカ、UAE、イスラエル、エジプト、その他の中東およびアフリカ）業界動向および2028年までの予測
市場分析と洞察: 中東およびアフリカのがんサポートケア製品市場
がんサポートケア製品市場は、2021年から2028年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に3.0％のCAGRで成長し、2020年の3億7,832万米ドルから2028年には4億7,540万米ドルに達すると分析しています。
がんサポートケア製品の需要の増加と政府の取り組みの強化は、予測期間中に市場の需要を押し上げる主な原動力です。がんサポートケア製品市場は、政府の取り組みの強化により、過去数年間で幅広い注目を集めています。さらに、がん疾患の発生率と有病率の増加、および製品の発売の増加も、市場の成長を後押ししています。
がんサポートケア製品市場の成長を牽引する主な要因は、がんの拡大を抑制するための政府の取り組みの増加であり、がんサポートケア製品市場の成長を妨げる要因は、がんサポートケア製品に関連する副作用です。主要な市場プレーヤーによる提携と買収は、世界のがんサポートケア製品市場の成長の機会として機能します。
がんサポートケア製品市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。
中東およびアフリカのがん治療サポート製品市場の範囲と市場規模
Middle East and Africa cancer supportive care products market is categorized into five notable segments which are based on drug type, type, cancer type, end user, and distribution channel.
- On the basis of drug type, the cancer supportive care products market is segmented into granulocyte colony stimulating factor (GCSFs), erythropoietin stimulating agents (ESA’s), opioid analgesics, monoclonal antibodies, nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, anti-emetics, and antihistamines and others. In 2021, granulocyte colony stimulating factor (GCSFs) segment is dominating the cancer supportive care products market as it stimulates the bone marrow and generates stem cells as well as granulocytes to discharge it in bloodstream. Moreover, granulocyte colony stimulating factor (GCSFS) is primarily used to treat and cure the neutropenia caused owing to cancer chemotherapy treatment.
- On the basis of type, the cancer supportive care products market is segmented into branded and generics. In 2021, generics segment is dominating the cancer supportive care products market since it is cost effective, easily accessible and primarily recommended by doctors for cancer supportive care products diseases.
- On the basis of cancer type, the cancer supportive care products market is segmented into lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukaemia, melanoma, ovarian cancer and other cancers. In 2021, the lung cancer segment is dominating the cancer supportive care products market due to growing smoking habits among populace in developed as well as developing country.
- On the basis of end user, the cancer supportive care products market is segmented into hospitals, clinics, hospitals & academic institutions and others. In 2021, hospitals segment is dominating the cancer supportive care products market as it provides patients with the best healthcare services. Moreover, hospitals are the primary healthcare service provider for patients suffering from cancer.
- On the basis of distribution channel, the cancer supportive care products market is segmented into hospital pharmacies, retail pharmacies and compounding pharmacies. In 2021, hospital pharmacies segment is dominating the cancer supportive care products market as most of the medicines are procured through hospital pharmacies. The increasing adoption of prescription based medicines, also acts as driver for the cancer supportive care products market growth.
Cancer Supportive Care Products Market Country Level Analysis
The cancer supportive care products market is analysed and market size information is provided by drug type, type, cancer type, end user and distribution channel.
The countries covered in the cancer supportive care products market report are Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa.
South Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028, in Middle East and Africa countries. The government organization and healthcare bodies are under taking various programs in this region, consequently it anticipated to propel the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Partnership and Distribution Agreement with Local Players, is Creating New Opportunities for Players in the Cancer supportive Care Products Market
Cancer supportive care products market also provides you with detailed market analysis for every country growth in cancer supportive care products product’s industry. Additionally, it provides detail information regarding growing partnership and distribution agreement with local players. The data is available for historic period 2011 to 2019.
Competitive Landscape and Cancer Supportive Care Products Market Share Analysis
Cancer supportive care products market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to cancer supportive care products market.
The major players covered in the report are Amgen Inc., Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Pfizer Inc., APR, Novartis AG, F. Hoffmann-La Roche Ltd., Acacia Pharma Group Plc., Baxter, Bayer AG, Helsinn Healthcare SA., Heron Therapeutics, Inc., Kyowa Kirin Co., Ltd., Acrotech Biopharma, Spectrum Pharmaceuticals, Inc., Oxford Pharmascience Ltd, Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.), Teva (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Tersera Therapeutics Llc., Mylan N.V., Sun Pharmaceutical Industries Ltd., among other Middle East and Africa players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
世界中の企業によって多くの製品の承認や契約も開始されており、これもがんサポートケア製品市場の拡大を加速させています。
- 2020年1月、ノバルティスAGは医薬品会社の買収を発表しました。この買収により、同社は世界中で地理的プレゼンスを拡大する新たな機会を得ることができました。また、同社の製品ポートフォリオのアップグレードにも役立っています。
市場プレーヤーによるコラボレーション、ジョイントベンチャー、その他の戦略により、がんサポートケア製品市場における企業の存在感が高まり、組織にも利益がもたらされます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DRUG TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EGULATORY
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 GROWING CANCER BURDEN WORLDWIDE
5.1.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS
5.1.3 GROWING GERIATRIC POPULATION
5.1.4 RISING NUMBER OF PRODUCT APPROVAL
5.1.5 RISING EXPENDITURE ON HEALTHCARE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER SUPPORTIVE DRUGS
5.2.2 LACK OF EARLY DETECTION
5.3 OPPORTUNITIES
5.3.1 ACQUISITION AND AGREEMENT BY MAJOR PLAYERS
5.3.2 RISING PRODUCT LAUNCHES
5.3.3 GROWING R&D ACTIVITIES
5.4 CHALLENGES
5.4.1 STRINGENT REGULATION POLICY
5.4.2 PATENT EXPIRY OF DRUGS
6 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS)
7.2.1 LONG ACTING FILGRASTIM
7.2.2 FILGRASTIM
7.2.3 LENOGRASTIM
7.3 ERYTHROPOIETIN STIMULATING AGENTS (ESA’S)
7.3.1 EPO-Α/Β
7.3.2 DPO
7.3.3 CERA
7.3.4 EPO-Κ
7.4 OPIOID ANALGESICS
7.4.1 FENTANYL
7.4.2 METHADONE
7.4.3 TRAMADOL
7.4.4 OTHERS
7.5 MONOCLONAL ANTIBODIES
7.6 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
7.6.1 OTC NSAIDS
7.6.1.1 ASPIRIN
7.6.1.2 IBUPROFEN
7.6.1.3 NAPROXEN SODIUM
7.6.2 PRESCRIPTION NSAIDS
7.6.2.1 CELECOXIB
7.6.2.2 DICLOFENAC
7.6.2.3 INDOMETHACIN
7.6.2.4 KETOROLAC
7.6.2.5 MELOXICAM
7.6.2.6 NABUMETONE
7.6.2.7 NAPROXEN
7.6.2.8 OXAPROZIN
7.6.2.9 PIROXICAM
7.6.2.10 SULINDAC
7.6.2.11 OTHERS
7.7 BISPHOSPHONATES
7.7.1 ZOLEDRONIC ACID OR ZOLEDRONATE
7.7.2 DISODIUM PAMIDRONATE
7.7.3 IBANDRONIC ACID OR IBANDRONATE
7.7.4 SODIUM CLODRONATE
7.8 ANTI-EMETICS
7.8.1 APREPITANT
7.8.2 DEXAMETHASONE
7.8.3 DOLASETRON
7.8.4 GRANISETRON
7.8.5 ONDANSETRON
7.8.6 PALONOSETRON
7.8.7 PROCHLORPERAZINE
7.8.8 ROLAPITANT
7.8.9 OTHERS
7.9 ANTIHISTAMINES
7.9.1 HYDROXYZINE
7.9.2 DIPHENHYDRAMINE
7.9.3 OTHERS
7.1 OTHERS
8 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE
8.1 OVERVIEW
8.2 BRANDED
8.2.1 NEULASTA
8.2.2 ARANESP
8.2.3 PROLIA
8.2.4 XGEVA
8.2.5 EPOGEN
8.2.6 EPREX
8.2.7 NEUPOGEN
8.2.8 OTHERS
8.3 GENERICS
9 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 LUNG CANCER
9.3 BREAST CANCER
9.4 PROSTATE CANCER
9.5 LIVER CANCER
9.6 BLADDER CANCER
9.7 LEUKAEMIA
9.8 MELANOMA
9.9 OVARIAN CANCER
9.1 OTHER CANCERS
10 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.2.1 ACUTE CARE HOSPITALS
10.2.2 LONG-TERM CARE HOSPITALS
10.2.3 NURSING FACILITIES
10.3 CLINICS
10.4 HOSPITALS & ACADEMIC INSTITUTIONS
10.5 OTHERS
11 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITAL PHARMACIES
11.3 RETAIL PHARMACIES
11.4 COMPOUNDING PHARMACIES
12 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY GEOGRAPHY
12.1 MIDDLE EAST & AFRICA
12.1.1 SOUTH AFRICA
12.1.2 SAUDI ARABIA
12.1.3 UAE
12.1.4 ISRAEL
12.1.5 EGYPT
12.1.6 REST OF MIDDLE EAST AND AFRICA
13 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
14 SWOT
15 COMPANY PROFILES
15.1 AMGEN INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 PFIZER INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOVARTIS AG
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 ACACIA PHARMA GROUP PLC
15.5.1 COMPANY SNAPSHOT
15.5.2 PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ACROTECH BIOPHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 APR
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 BAXTER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 HELSINN HEALTHCARE SA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 HERON THERAPEUTICS, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 KYOWA KIRIN CO., LTD.
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 MYLAN N.V.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENTS
15.16 OXFORD PHARMASCIENCE LTD
15.16.1 COMPANY SNAPSHOT
15.16.2 TECHNOLOGY PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SPECTRUM PHARMACEUTICALS, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 TERSERA THERAPEUTICS LLC
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表のリスト
LIST OF TABLES
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 MORTALITY DUE TO CANCER, AGES 85+, IN THE U.S.
TABLE 3 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2020-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE 2020-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENERICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2020-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA LUNG CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA BREAST CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA LIVER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA BLADDER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA LEUKAEMIA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA MELANOMA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OVARIAN CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA OTHER CANCERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA CLINICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA HOSPITALS & ACADEMIC INSTITUTIONS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA COMPOUNDING PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 64 SOUTH AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 SOUTH AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 80 SAUDI ARABIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 96 UAE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 97 UAE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 98 UAE ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 UAE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 100 UAE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 UAE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 102 UAE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 103 UAE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 104 UAE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 105 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 UAE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 108 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 109 UAE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 110 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 111 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 112 ISRAEL GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 128 EGYPT GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 129 EGYPT OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 130 EGYPT ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 131 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 132 EGYPT OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 133 EGYPT PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 134 EGYPT BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 135 EGYPT ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 136 EGYPT ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 137 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 EGYPT BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 139 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 140 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 141 EGYPT HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 142 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 143 REST OF MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
図表一覧
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 10 GROWING CANCER BUREN WORLDWIDE IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 14 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES (WORLD) IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 15 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020
FIGURE 16 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020
FIGURE 24 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020
FIGURE 28 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 32 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020)S
FIGURE 36 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020)
FIGURE 37 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 38 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028)
FIGURE 40 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
